heart-rhythm

Xarelto is under FDA review for long-term use in patients with atrial fibrillation, a heart-rhythm disorder that puts people at risk of a stroke.

Bayer, J&J Suffer FDA Setback Jennifer Corbett Dooren 2011

Eliquis, which Bristol-Myers has co-developed with Pfizer Inc., also has been studied to prevent stroke in people with a heart-rhythm disorder, a bigger patient population that is expected to boost the drug's sales.

Bristol-Myers Net Falls, but Plavix Sales Are Up Peter Loftus 2011

St. Jude Medical Inc. 's third-quarter earnings rose 25% as the company contained costs and posted a double-digit sales gain for implantable defibrillators, but the company raised questions about future growth by saying the market for heart-rhythm devices isn't expanding as fast as hoped.

St. Jude Profit Rises 25% Amid Questions on Future Growth Jon Kamp 2010

European regulators on Thursday limited use of the heart-rhythm drug Multaq for safety reasons, and the U.S. Food and Drug Administration expects to take similar or tougher action in coming weeks, according to people familiar with the FDA deliberations.

Use of Heart Drug Restricted in Europe Thomas M. Burton 2011

Specifically, St. Jude now expects about 3% yearly growth in the heart-rhythm market, excluding the impact of currency rates, down from a forecast of 4% to 6% growth the company backed just three months ago.

St. Jude Profit Rises 25% Amid Questions on Future Growth Jon Kamp 2010

This offset flat growth in pacemakers to push overall heart-rhythm sales up 7% to $738 million.

St. Jude Profit Rises 25% Amid Questions on Future Growth Jon Kamp 2010

About 59% of its sales came from a market for heart-rhythm devices — pacemakers and defibrillators — that grew slower than the corporate average.

St. Jude Agrees to Buy AGA Medical for $1.1 Billion Jon Kamp 2010

The company's biggest businesses are for heart-artery stents and implantable heart-rhythm devices like defibrillators and pacemakers.

Boston Scientific Recalls Stent Jon Kamp 2011

Sales of heart-rhythm management devices, including implantable cardioverter defibrillators, fell 9.5% world-wide — 10% in the U.S. and 7.8% abroad.

Boston Scientific Swings to Profit John Kell 2010

Medtronic, which has been facing challenges in the markets for heart-rhythm and spinal devices—the company's biggest businesses—said it expects to use some of the proceeds to offset any potential dilutive impact for the transaction.

Bain Capital to Buy Medtronic Unit Tess Stynes 2011